Form 4: TriSalus Life Sciences Director, Sean Murphy, Reports Acquisition of Shares

Director Sean Murphy reports acquiring shares of TriSalus Life Sciences, Inc. through restricted stock units.

Summary

• On May 19, 2025, Sean Murphy, a director of TriSalus Life Sciences, Inc. acquired 44,884 shares of common stock at a price of $5.18 per share.
• These shares were acquired through the vesting of restricted stock units (RSUs).
• Following this transaction, Murphy directly owns 123,989 shares.
• Murphy also indirectly owns 357,535 shares through the Murphy Family Trust 2012 and 197,732 shares through Sean E Murphy TTEE U/A 2/4/2004.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's share acquisition, which can be interpreted as a sign of confidence, but without further context, it's difficult to gauge the overall impact.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the financial industry to gauge company health and management confidence.
• Comparing Sean Murphy's holdings and transactions to those of other directors in similar biotech companies can provide insights into relative ownership stakes and investment behavior.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates

Keywords

TriSalus Life Sciences, Sean Murphy, Director, Share Acquisition, Form 4, Beneficial Ownership, TLSI, Restricted Stock Units, RSUs